ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Epithelial Carcinoma

Triple Negative Breast Cancer trials near Taipei City, TWN:

Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (ESCALATE)

in augmenting neoadjuvant therapy for patients with premenopausal breast cancer.For triple negative breast...

Enrolling
Triple Negative Breast Cancer
Premenopausal Breast Cancer
Drug: Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg

Phase 2

National Taiwan University
National Taiwan University

Taipei, Taiwan

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Trastuzumab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Taipei, Taiwan and 31 other locations

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Active, not recruiting
Breast Cancer
Drug: Tobemstomig
Drug: Nab-Paclitaxel

Phase 2

Roche
Roche

Taipei, Taiwan and 60 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Taipei City, Taiwan and 226 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Taipei, Taiwan and 516 other locations

after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Taiwan and 121 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Taipei, Taiwan and 505 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Active, not recruiting
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Taipei, Taiwan and 275 other locations

, and anti-tumor activity of each regimen at the MTD/RD....

Active, not recruiting
Triple Negative Breast Cancer
Microsatellite Stable Colorectal Cancer
Drug: DKY709
Drug: PDR001

Phase 1

Novartis
Novartis

Taipei, Taiwan and 8 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Beitou, Taiwan and 192 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems